2017
A systematic analysis of FDA-approved anticancer drugs
Sun J, Wei Q, Zhou Y, Wang J, Liu Q, Xu H. A systematic analysis of FDA-approved anticancer drugs. BMC Systems Biology 2017, 11: 87. PMID: 28984210, PMCID: PMC5629554, DOI: 10.1186/s12918-017-0464-7.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsDrug ApprovalHumansMolecular Targeted TherapyNeoplasmsUnited StatesUnited States Food and Drug AdministrationConceptsDrug-cancer associationsAnticancer drugsTarget-based drugsEfficient anticancer drugsTarget-based approachCancer typesNew anticancer drugsNovel anticancer drugsClinical trial studyPharmaceutical researchTrial studyMore cancer typesUS FoodDrug AdministrationCytotoxic drugsPatient treatmentPotential candidateDrug mechanismsDrugsDrug repurposingSystematic investigationAssociationDrug targetsTyrosine kinaseSystematic discovery
2015
A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case
Huang L, Soysal E, Zheng W, Zhao Z, Xu H, Sun J. A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case. BMC Systems Biology 2015, 9: s2. PMID: 26100720, PMCID: PMC4474536, DOI: 10.1186/1752-0509-9-s4-s2.Peer-Reviewed Original Research